Could Trump Make A Big Weight Loss Drug Deal? [Forbes]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Forbes
UCG/Universal Images Group via Getty Images President-elect Donald Trump prides himself on making deals. Here is one for him: Keep Joe Biden's commitment to have Medicare pay for GLP-1 drugs such as Ozempic and Wegovy for weight loss. But only if the drugmakers agree to substantially reduce their prices right away. Such a move would be fraught for Trump and his Republican allies on multiple levels. But it presents the incoming president with a major political opportunity as well as some significant challenges. And not doing the deal brings its own risks. The Backstory While Medicare pays for the GLP-1 drugs for people with Type-2 diabetes and some forms of heart disease, it has been barred by an old federal law from paying for weight-loss drugs. But last November President Biden proposed new rules to allow Medicare and Medicaid to pay for these meds. The change would not become final until after Trump is inaugurated, dropping the issue squarely in his lap. Over the past few
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk seeks to block compounded Victoza [Seeking Alpha]Seeking Alpha
- Lilly asks to join lawsuit over compounded versions of its weight-loss drugs [CNBC]CNBC
- GLP-1 questions emerge for 2025 [Yahoo! Finance Canada]Yahoo! Finance Canada
- GLP-1 questions emerge for 2025 [Yahoo! Finance]Yahoo! Finance
- Why Novo Nordisk (NVO) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/7/24 - Beat
NVO
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/18/24 - Form 6-K
- NVO's page on the SEC website